Clin Asst Prof Wong Fuh Yong

Dr Wong Fuh Yong is a Senior Consultant with the Division of Radiation Oncology, NCCS. He received his medical education at NUS and qualified as a Clinical Oncologist with the Royal college of Radiology, UK in 2007. He specializes in breast oncology, neuro-oncology and the use of stereo-tactic radiosurgery for both benign and malignant indications. He is active in research in breast cancers and has published in several peer reviewed journals. He has received support and funding from various agencies to introduce new treatment modality into NCCS and Singapore. He is currently engaged in running several local studies in breast, prostate and brain cancers as well as international collaborative trials with UK and the USA. In addition, he is interested in the health economics of cancer care and cancer epidemiology and is in several collaborations involving researchers from other hospitals and government agencies including NUH, TTSH, KKWCH and A-star. He is also involved in cross border collaborative research with hospitals in the region.

• Fellow of Royal Of Radiologist (Clinical Oncology) - 2006 
• Bachelors in Medicine, Bachelors in Surgery (MBBS) From NUS - 1998

• ​NCCS Post Graduate Education Committee Member - 2008 present

• ​Ministry of Education Scholarship 1992 - 1993 
• Ministry of Education Full Sponsorship to London International Youth Science Fortnight 1993 
• HMDP 2005 - 2007
• 2012 Best paper of the year in “Annals, Academy of Medicine Best Publication” Award

• Outcomes of Low-Risk Ductal Carcinoma in situ in South East Asian Women treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):998-1003. 
• Assessment of the American Joint Committee on Cancer 7th edition staging for localized prostate cancer in Asia treated with external beam radiotherapy. Ann Acad Med Singapore 2014 
• Validation of a Nomogram in the Prediction of Local Recurrence Risks after Conserving Surgery for Asian Women with Ductal Carcinoma in Situ of the Breast. Clin Oncol (R Coll Radiol). 2014 Nov;26(11):684-91 
• Hormone Receptors and HER-2 Status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conser-vation therapy. Ann Acad Med Singapore 2011;40:90-6